API | brolucizumab-dbll

brolucizumab-dbll (Beovu) Report issue

Biologics mAb Approved ^FDA

AACT

Active Ingredient History

NOW

Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
brolucizumab

More Chemistry

Pharmacology

Mechanism of Action:
- Vascular endothelial growth factor A (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

esba1008 | lmg324 | rth258

Organizations (12)

Research & Development (12)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (1)

Wet Macular Degeneration (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (12)

Choroidal Neovascularization (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetic Retinopathy (Phase 3)

Eye Diseases (Phase 4)

Macular Degeneration (Phase 4)

Macular Edema (Phase 3)

Polypoidal Choroidal Vasculopathy (Phase 3)

Retinal Degeneration (Phase 4)

Retinal Diseases (Phase 4)

Retinal Dystrophies (Phase 4)

Retinal Vein Occlusion (Phase 3)

Wet Macular Degeneration (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 37
# of Trial Organizations: 12

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue